SillaJen is Biotechnology in South Korea that focus on SillaJen Biotherapeutics business. Founded in 2006. They cover business area such as SillaJen Inc, cancer treatment cell, its subsidiary, SillaJen Biotherapeutics, Pexa-Vec, an oncolytic virus, antibody, improve survival, an engineer vaccinia virus strain, cancer cell, viral attack, its business activity, Korea, United States.
2006
( 18 years old in 2024 )
SillaJen Biotherapeutics
-
11th Floor, O2 Tower, 83 Uisadang-daero
Yeongdeungpo-gu
Seoul, 07325
South Korea
Private
SillaJen Inccancer treatment cellits subsidiarySillaJen BiotherapeuticsPexa-Vecan oncolytic virusantibodyimprove survivalan engineer vaccinia virus straincancer cellviral attackits business activityKoreaUnited States
* We use standard office opening hours in near SillaJen's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
SillaJen is Biotechnology business from South Korea that founded in 2006 (18 years old in 2024), SillaJen business is focusing on SillaJen Biotherapeutics.
SillaJen headquarter office and corporate office address is located in 11th Floor, O2 Tower, 83 Uisadang-daero Yeongdeungpo-gu Seoul, 07325 South Korea.
SillaJen was founded in South Korea.
In 2024, SillaJen is currently focus on SillaJen Biotherapeutics sector.
Above is snippet of Google Trends for "SillaJen Biotherapeutics" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with SillaJen, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
